Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Sign Up to like & getrecommendations! Published in 2018 at "International journal of oncology"
DOI: 10.3892/ijo.2018.4456
Abstract: The objective of cancer immunotherapy is to prime the host's immune system to recognize and attack malignant tumor cells. IMO‑2125, a Toll‑like receptor 9 (TLR9) agonist, exhibited potent antitumor effects in the murine syngeneic A20 lymphoma and… read more here.
Keywords: administration; imo 2125; ct26; antitumor ... See more keywords